Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
Abstract
Aims: Nausea and vomiting accompany pregnancy, gastroenteritis, migraine, the perioperative period, and cytotoxic chemotherapy, and antiemetics are among the most frequently prescribed drugs worldwide. Several antiemetic classes delay ventricular repolarization and prolong the QT interval, a substrate for torsades de pointes (TdP), ventricular fibrillation, and sudden cardiac death. We synthesized the evidence on antiemetic QT liability and translated it into a three-tier, risk-stratified prescribing framework and stepwise clinical algorithm for patients with inherited or acquired long QT syndrome (LQTS) and other torsadogenic risk factors.
Methods and results: We conducted a narrative review of PubMed/MEDLINE, EMBASE, and pharmacovigilance sources (FDA Adverse Event Reporting System, CredibleMeds/QTdrugs) through early 2026, prioritizing mechanistic studies, randomized comparisons, disproportionality analyses, and consensus statements on antiemetic QT liability and LQTS management.QT prolongation across antiemetic classes is driven principally by IKr blockade (hERG/KCNH2). Risk is highly heterogeneous within classes: in a 2026 FAERS disproportionality analysis, ondansetron carried a substantially stronger QT-related signal than olanzapine (reporting odds ratio 27.2 vs. 8.7), consistent with its dose-dependent effect among 5-HT3 antagonists, which prompted a 2012 FDA restriction on the 32 mg intravenous dose; palonosetron has minimal effect. Neurokinin-1 antagonists, low-risk antihistamines, anticholinergics, and 5-HT4 agonists carry little QT liability, while butyrophenones, phenothiazines, and promethazine carry greater risk. Serious events cluster in patients with electrolyte disturbance, bradycardia, polypharmacy, or underlying LQTS, particularly when QTc exceeds 500 ms or rises more than 60 ms from baseline.
Conclusion: Antiemetic-associated arrhythmia is largely preventable. Structured risk assessment, electrolyte correction, ECG monitoring, and a stepwise selection strategy favouring agents with minimal QT liability allow clinicians to manage nausea and vomiting safely, even in high-risk populations.
Related
- Clinical characteristics of cadonilimab-associated infusion reactions: a severity-stratified analysis of 52 cases and preliminary management framework
- A Conceptual Translational Bench-to-Bedside Cardiac Safety Framework for Predicting Drug-Induced QT Interval Prolongation from Molecular Structure to Clinical Data
- Zolpidem Intoxication Associated with Probable Reverse Stress-Induced Cardiomyopathy and QT Prolongation: A Case Report
- A risk-stratified dynamic screening framework for age-related macular degeneration via a clustering-based partially observable markov decision process
- EHR-Based Quality Interventions Associated With Differential GDMT Prescribing in Community Versus Academic Hospitals
BibTeX
@article{moustafa2026antiemeticassociated,
title = {{Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome}},
author = {Ahmed T Moustafa and Omar Dabash and Pradosh Kumar Panigrahi and Habib Rehman Khan},
journal = {European Heart Journal. Cardiovascular Pharmacotherapy},
year = {2026},
month = sep,
doi = {10.1093/ehjcvp/pvag077},
url = {https://doi.org/10.1093/ehjcvp/pvag077},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
AU - Ahmed T Moustafa
AU - Omar Dabash
AU - Pradosh Kumar Panigrahi
AU - Habib Rehman Khan
PY - 2026
DA - 2026/09/16
JO - European Heart Journal. Cardiovascular Pharmacotherapy
DO - 10.1093/ehjcvp/pvag077
UR - https://doi.org/10.1093/ehjcvp/pvag077
AB - Aims: Nausea and vomiting accompany pregnancy, gastroenteritis, migraine, the perioperative period, and cytotoxic chemotherapy, and antiemetics are among the most frequently prescribed drugs worldwide. Several antiemetic classes delay ventricular repolarization and prolong the QT interval, a substrate for torsades de pointes (TdP), ventricular fibrillation, and sudden cardiac death. We synthesized the evidence on antiemetic QT liability and translated it into a three-tier, risk-stratified prescribing framework and stepwise clinical algorithm for patients with inherited or acquired long QT syndrome (LQTS) and other torsadogenic risk factors. Methods and results: We conducted a narrative review of PubMed/MEDLINE, EMBASE, and pharmacovigilance sources (FDA Adverse Event Reporting System, CredibleMeds/QTdrugs) through early 2026, prioritizing mechanistic studies, randomized comparisons, disproportionality analyses, and consensus statements on antiemetic QT liability and LQTS management.QT prolongation across antiemetic classes is driven principally by IKr blockade (hERG/KCNH2). Risk is highly heterogeneous within classes: in a 2026 FAERS disproportionality analysis, ondansetron carried a substantially stronger QT-related signal than olanzapine (reporting odds ratio 27.2 vs. 8.7), consistent with its dose-dependent effect among 5-HT3 antagonists, which prompted a 2012 FDA restriction on the 32 mg intravenous dose; palonosetron has minimal effect. Neurokinin-1 antagonists, low-risk antihistamines, anticholinergics, and 5-HT4 agonists carry little QT liability, while butyrophenones, phenothiazines, and promethazine carry greater risk. Serious events cluster in patients with electrolyte disturbance, bradycardia, polypharmacy, or underlying LQTS, particularly when QTc exceeds 500 ms or rises more than 60 ms from baseline. Conclusion: Antiemetic-associated arrhythmia is largely preventable. Structured risk assessment, electrolyte correction, ECG monitoring, and a stepwise selection strategy favouring agents with minimal QT liability allow clinicians to manage nausea and vomiting safely, even in high-risk populations.
SN - 2055-6837
SN - 2055-6845
ER -